This biotech's ONE drug could change medicine as we know it

[Click here to unsubscribe](    [This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses with Potentially ONE Drug](  The public company’s lead drug candidate NV-387, a drug that treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials.  A broad-spectrum antiviral drug such as this one would be a highly desirable drug globally because it would enable treatment of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. What else does this? Antibiotics.  The technology behind this could completely transform the way viruses and their variants are treated worldwide and there’s a good chance this public company holds the golden ticket.  As biotech stages a big comeback, this is a company you’ll want to have on your radar. [Click here to learn more about the incredible investment opportunity this organization may provide.](  ---------------------------------------------------------------      This email was sent to {EMAIL} by editor@marketmovingtrends.com MarketMovingTrends c/o CLM Media LLC, 45 South Park Place, #203, Morristown, NJ 07960 United States  [Unsubscribe]( | [Report Spam]( Â